"Supreme Court Abortion Pill Case Sparks Potential Challenges to Other Drugs"

The Supreme Court is considering a challenge to the FDA's decision to make the abortion pill mifepristone more accessible, which could have far-reaching implications for other drugs such as vaccines, birth control pills, hormone therapies, and fertility drugs. The pharmaceutical industry warns that allowing individual federal judges to override the FDA's scientific findings could lead to widespread litigation and hinder innovation. The case does not directly focus on abortion itself but on whether the FDA followed the correct processes in easing restrictions on mifepristone, with potential implications for drug regulation and approval processes.